MEDIFAST INC (MED)
Official siteCONSUMER CYCLICAL • PERSONAL SERVICES • NYSE
Market Cap: $145.04M
Last updated: Nov 17, 2026 at 11:06 AM ET
MEDIFAST INC (MED) Earnings: Report Dates and Results
MEDIFAST INC (MED) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, MEDIFAST INC reported EPS of -$0.19, above the -$0.40 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MED has an expected report date of Feb 15, 2027.
MED Earnings Call
The latest MED earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MED beat 33, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $72.05M, down 19.4% from $89.41M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.19 | -$0.40 | N/A | +52.50% | Beat | N/A | 1 | 1 up, 0 down | Oct 26, 2026 | $72.05M |
| Jun 30, 2026 | -$0.28 | -$0.67 | N/A | +58.21% | Beat | -227.3% | 1 | 0 up, 1 down | Aug 3, 2026 | $76.38M |
| Mar 31, 2026 | -$0.19 | -$0.52 | -$0.52 - -$0.52 | +63.46% | Beat | N/A | 1 | 0 up, 1 down | May 4, 2026 | $76.04M |
| Dec 31, 2025 | -$1.65 | -$0.45 | N/A | -266.67% | Miss | -1750.0% | 1 | 1 up, 0 down | Feb 17, 2026 | $75.10M |
| Sep 30, 2025 | -$0.21 | -$0.36 | -$0.36 - -$0.36 | +41.67% | Beat | -160.0% | 1 | 1 up, 0 down | Nov 3, 2025 | $89.41M |
| Jun 30, 2025 | $0.22 | -$0.19 | -$0.19 - -$0.19 | +215.79% | Beat | -76.1% | 1 | 0 up, 1 down | Aug 4, 2025 | $105.56M |
| Mar 31, 2025 | -$0.07 | -$0.25 | -$0.25 - -$0.25 | +72.00% | Beat | -110.6% | 1 | 0 up, 1 down | Apr 28, 2025 | $115.73M |
| Dec 31, 2024 | $0.10 | $0.24 | N/A | -58.75% | Miss | -81.8% | 2 | 2 up, 0 down | Feb 18, 2025 | $119.00M |
| Sep 30, 2024 | $0.35 | -$0.28 | -$0.40 - -$0.15 | +225.00% | Beat | -83.5% | 2 | 0 up, 0 down | Nov 4, 2024 | $140.16M |
| Jun 30, 2024 | $0.92 | $0.39 | $0.38 - $0.40 | +135.90% | Beat | -66.8% | 2 | 1 up, 0 down | Aug 5, 2024 | $168.56M |
| Mar 31, 2024 | $0.66 | $0.80 | $0.74 - $0.82 | -17.50% | Miss | -82.0% | 2 | 0 up, 0 down | Apr 29, 2024 | $174.74M |
| Dec 31, 2023 | $0.55 | $0.96 | $0.93 - $0.99 | -42.71% | Miss | -83.2% | 2 | 1 up, 0 down | Feb 20, 2024 | $191.01M |
| Sep 30, 2023 | $2.12 | $1.07 | $1.02 - $1.11 | +98.13% | Beat | -36.1% | 2 | 0 up, 0 down | Nov 6, 2023 | $235.87M |
| Jun 30, 2023 | $2.77 | $1.44 | $1.44 - $1.44 | +92.36% | Beat | -28.4% | 1 | 0 up, 0 down | Aug 7, 2023 | $296.19M |
| Mar 31, 2023 | $3.67 | $2.40 | $2.40 - $2.40 | +52.92% | Beat | +2.2% | 1 | 0 up, 0 down | May 1, 2023 | $348.98M |
| Dec 31, 2022 | $3.27 | $2.22 | $2.22 - $2.22 | +47.30% | Beat | +12.4% | 1 | 0 up, 0 down | Feb 21, 2023 | $337.25M |
| Sep 30, 2022 | $3.32 | $1.91 | $1.91 - $1.91 | +73.82% | Beat | -6.7% | 1 | 0 up, 0 down | Nov 3, 2022 | $390.40M |
| Jun 30, 2022 | $3.87 | $3.23 | $2.98 - $3.57 | +19.81% | Beat | -2.3% | 3 | 0 up, 1 down | Aug 3, 2022 | $453.33M |
| Mar 31, 2022 | $3.59 | $3.57 | $3.43 - $3.68 | +0.56% | Beat | +3.8% | 3 | 1 up, 0 down | May 2, 2022 | $417.60M |
| Dec 31, 2021 | $2.91 | $2.65 | $2.62 - $2.68 | +9.81% | Beat | +23.3% | 3 | N/A | Feb 23, 2022 | $377.83M |
| Sep 30, 2021 | $3.56 | $2.92 | $2.42 - $3.42 | +21.92% | Beat | +22.3% | 3 | 0 up, 0 down | Nov 4, 2021 | $413.39M |
| Jun 30, 2021 | $3.96 | $3.30 | $3.06 - $3.54 | +20.00% | Beat | +102.0% | 3 | N/A | Aug 4, 2021 | $394.19M |
| Mar 31, 2021 | $3.46 | $2.72 | $2.61 - $2.89 | +27.21% | Beat | +79.3% | 4 | N/A | May 4, 2021 | $340.67M |
| Dec 31, 2020 | $2.36 | $2.38 | $2.20 - $2.60 | -0.84% | Miss | +42.2% | 5 | N/A | Feb 25, 2021 | $264.91M |
| Sep 30, 2020 | $2.91 | $2.49 | $2.31 - $2.74 | +16.87% | Beat | +120.5% | 4 | N/A | Nov 2, 2020 | $271.47M |
| Jun 30, 2020 | $1.96 | $1.84 | $1.80 - $1.89 | +6.52% | Beat | +12.0% | 4 | N/A | Aug 5, 2020 | $220.00M |
| Mar 31, 2020 | $1.93 | $1.33 | $1.21 - $1.42 | +45.11% | Beat | +13.5% | 3 | N/A | May 5, 2020 | $178.46M |
| Dec 31, 2019 | $1.66 | $1.08 | $1.06 - $1.10 | +53.70% | Beat | +27.7% | 4 | N/A | Feb 26, 2020 | $170.63M |
| Sep 30, 2019 | $1.32 | $1.33 | $1.32 - $1.35 | -0.75% | Miss | +15.8% | 4 | N/A | Nov 7, 2019 | $190.06M |
| Jun 30, 2019 | $1.75 | $1.72 | $1.70 - $1.74 | +1.74% | Beat | +50.9% | 4 | N/A | Aug 1, 2019 | $187.10M |
| Mar 31, 2019 | $1.70 | $1.53 | $1.52 - $1.55 | +11.11% | Beat | +68.3% | 3 | N/A | May 1, 2019 | $165.88M |
| Dec 31, 2018 | $1.30 | $1.21 | $1.19 - $1.24 | +7.44% | Beat | +116.7% | 3 | N/A | Feb 26, 2019 | $145.84M |
| Sep 30, 2018 | $1.14 | $1.14 | $1.13 - $1.15 | 0.00% | In line | +107.3% | 3 | N/A | Nov 6, 2018 | $139.24M |
| Jun 30, 2018 | $1.16 | $0.98 | $0.96 - $1.05 | +18.37% | Beat | +84.1% | 3 | N/A | Aug 2, 2018 | $117.32M |
| Mar 31, 2018 | $1.01 | $0.86 | $0.86 - $0.87 | +17.44% | Beat | +98.0% | 3 | N/A | May 3, 2018 | $98.60M |
| Dec 31, 2017 | $0.60 | $0.48 | $0.48 - $0.48 | +25.00% | Beat | +76.5% | 3 | N/A | Mar 6, 2018 | $78.01M |
| Sep 30, 2017 | $0.55 | $0.51 | $0.51 - $0.51 | +7.84% | Beat | +7.8% | 2 | N/A | Nov 7, 2017 | $77.20M |
| Jun 30, 2017 | $0.63 | $0.52 | $0.52 - $0.52 | +21.15% | Beat | 0.0% | 1 | N/A | Aug 8, 2017 | $75.73M |
| Mar 31, 2017 | $0.51 | $0.47 | N/A | +8.51% | Beat | +21.4% | N/A | N/A | May 4, 2017 | $70.62M |
| Dec 31, 2016 | $0.34 | $0.33 | N/A | +3.03% | Beat | +3.0% | N/A | N/A | Mar 9, 2017 | $62.47M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after $2.03 the year before. It was $1.90 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.71 | -184.2% |
| Dec 31, 2024 | $2.03 | -77.7% |
| Dec 31, 2023 | $9.11 | -35.2% |
| Dec 31, 2022 | $14.05 | +1.2% |
| Dec 31, 2021 | $13.89 | +51.6% |
| Dec 31, 2020 | $9.16 | +42.5% |
| Dec 31, 2019 | $6.43 | +39.5% |
| Dec 31, 2018 | $4.61 | +101.3% |
| Dec 31, 2017 | $2.29 | +20.5% |
| Dec 31, 2016 | $1.90 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,866 | 5 | |
| 2026Q2 | Jun 30, 2026 | 4,211 | 5 | |
| 2026Q1 | Mar 31, 2026 | 5,206 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,406 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,204 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,627 | 6 | |
| 2025Q1 | Mar 31, 2025 | 5,010 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,579 | 6 |
2026Q3 Earnings Call
Opening remarks
Steven Zenker Manager of Investor Relations Good morning, and welcome to Medifast's third quarter 2026 Earnings Conference Call. On the call with me today are Nicholas Johnson, Chief Executive Officer, and James Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the third quarter ended September 30, 2026, which went out this morning at approximately 8:05 a.m. Eastern Time. If you have not received the release, it is available on the investor relations portion of Medifast's website at www.medifastinc.com. This call is being webcast, and a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements. These statements do not guarantee future performance and, therefore, undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chief Executive Officer, Nicholas Johnson.
Nicholas Johnson Chief Executive Officer Thanks, Steven, and good morning, everyone. Thanks for joining us on the call today and for your continued interest in Medifast. Our third quarter was all about execution. With our new brand, Trilogy, now live, new products available, and an enhanced compensation plan and unified coach training platform launched, our 3.0 business is rolling out. Early results are already showing up in the field. We delivered revenue in line with guidance at $72 million, continuing the trend of stabilizing revenue around $75 million for the fourth consecutive quarter. Coach productivity continues to improve. We believe these trends leave us well positioned to deliver profitability in the fourth quarter. We ended the quarter with $173 million in cash and investments and no debt. Our enterprise value continues to sit below the value of our cash and investments. A debt-free balance sheet and a leaner cost structure give us a stable base from which to grow and invest in initiatives that can help deliver scale and profitability. Trilogy is differentiating Medifast in a large and growing metabolic health market, a market that we believe our coaches are well positioned to own. Over the past few months, we launched the Medifast Metabolic Health Institute, introduced our MetaVantage technology ingredient platform, and brought new products and training to market that are designed to give us a solid foundation to deliver for clients in the metabolic health category.
Frequently Asked Questions About MED
When is MEDIFAST INC's next earnings date?
MEDIFAST INC's next earnings report is expected for Feb 15, 2027.
Did MED beat earnings estimates last quarter?
Yes. MEDIFAST INC reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.40 estimate, a 52.50% surprise.
What EPS do analysts expect from MED next quarter?
The consensus EPS estimate for MEDIFAST INC for the quarter ending Dec 31, 2026 is $0.01 from 2 analysts, with estimates from $0.01 to $0.01.
How often does MED beat earnings estimates?
MEDIFAST INC beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.28%.
MED pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors